Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced a significant milestone in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital: patient enrollment has reached the halfway mark. The study, which uses a novel PET imaging technique with the [¹⁸F]3F4AP tracer, aims to directly assess demyelination in the brain. Preliminary imaging data have shown encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, which may improve the understanding and treatment of MS.
This imaging approach could enhance the development of MS therapies, including Quantum’s investigational candidate Lucid-MS. In March 2026, the company submitted an Investigational New Drug (IND) application to the FDA for a Phase 2 trial of Lucid-MS. The ability to directly visualize demyelination through PET imaging may provide a more precise tool for evaluating the efficacy of treatments like Lucid-MS, which is designed to prevent and reverse myelin degradation.
The study's progress is a critical step forward for Quantum BioPharma, as it not only supports the development of Lucid-MS but also establishes a potential biomarker for MS. The company believes that this imaging technique could become a standard in clinical trials for MS therapies, offering a non-invasive way to monitor disease progression and treatment response.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on advancing Lucid-MS, a patented new chemical entity that has shown promise in preclinical models. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets the over-the-counter product UNBUZZD, and receives royalty payments from its sales.
For more details on the study and the company's pipeline, visit the full press release here. Additional updates on Quantum BioPharma can be found in the company’s newsroom at https://ibn.fm/QNTM.
